BEAM / Beam Therapeutics up 10% on $600m Lilly deal

Cathie Wood, the brilliant mind behind ARK Invest, is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have more_horizontal

Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics to Eli Lilly and C more_horizontal

Beam recently announced a reorganization that involves layoffs and a narrowing of its pipeline. The company lost $82.8 million in the second quarter. more_horizontal

Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease treatment; Data expected in 2024. more_horizontal

Pre-revenue biotechs like Beam Therapeutics bring plenty of risk. The good news is that it has plenty of money and some help from Pfizer, too. more_horizontal

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its wo more_horizontal

Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructurin more_horizontal

Beam Therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash more_horizontal